{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:35:36Z","timestamp":1783035336977,"version":"3.54.6"},"reference-count":24,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,30]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Nearly half of patients with multiple myeloma (MM) have hyperdiploidy (HMM) at diagnosis. Although HMM occurs early, the mutational processes before and after hyperdiploidy are still unclear. Here, we used 72 whole-genome sequencing samples from patients with HMM and identified pre- and post-HMM mutations to define the chronology of the development of hyperdiploidy. An MM cell accumulated a median of 0.56 mutations per megabase before HMM, and for every clonal pre-HMM mutation, 1.21 mutations per megabase accumulated after HMM. This analysis using mutations before and after hyperdiploidy shows that hyperdiploidy happens after somatic hypermutation. Prehyperdiploidy mutations are activation-induced cytidine deaminase and age\/clock-like signature driven, whereas posthyperdiploidy mutations are from DNA damage and APOBEC. Interestingly, the first hyperdiploidy event occurred within the first 3 decades of life and took a decade to complete. Copy number changes affecting chromosomes 15 and 19 occurred first. Finally, mutations before initiating event affected chromosomes at different rates, whereas post\u2013initiating event mutational processes affect each chromosome equally.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025250","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T21:32:55Z","timestamp":1732224775000},"page":"520-525","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Development of hyperdiploidy starts at an early age and takes a decade to complete"],"prefix":"10.1182","volume":"145","author":[{"given":"Mehmet K.","family":"Samur","sequence":"first","affiliation":[{"name":"1Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-0562","authenticated-orcid":false,"given":"Anil","family":"Aktas Samur","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Shah","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"4Department of Hematology, Dartmouth Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-0344","authenticated-orcid":false,"given":"Joseph S.","family":"Park","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Shammas","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[{"name":"5Unit\u00e9 de Genomique du My\u00e9lome, University Cancer Center of Toulouse Institut National de la Sant\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8783-5961","authenticated-orcid":false,"given":"Giovanni","family":"Parmigiani","sequence":"additional","affiliation":[{"name":"1Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-0140","authenticated-orcid":false,"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"5Unit\u00e9 de Genomique du My\u00e9lome, University Cancer Center of Toulouse Institut National de la Sant\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"6Veterans Affairs Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"27","key":"2025013016203216700_bib1","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025013016203216700_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int J Hematol"},{"key":"2025013016203216700_bib3","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"2025013016203216700_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2016.70.6705","article-title":"Genomics of multiple myeloma","volume":"35","author":"Robiou du Pont","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2025013016203216700_bib5","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.20.00461","article-title":"Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group","volume":"38","author":"Samur","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2025013016203216700_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2025013016203216700_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-019-0199-3","article-title":"Deciphering the chronology of copy number alterations in multiple myeloma","volume":"9","author":"Aktas Samur","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025013016203216700_bib8","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"key":"2025013016203216700_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/1471-2164-14-672","article-title":"The shaping and functional consequences of the dosage effect landscape in multiple myeloma","volume":"14","author":"Samur","year":"2013","journal-title":"BMC Genomics"},{"key":"2025013016203216700_bib10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","article-title":"Cell of origin and genetic alterations in the pathogenesis of multiple myeloma","volume":"10","author":"Barwick","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"2025013016203216700_bib11","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"2025013016203216700_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2025013016203216700_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2025013016203216700_bib14","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"2025013016203216700_bib15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.2024024299","article-title":"The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma","volume":"144","author":"Cirrincione","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025013016203216700_bib16","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"2025013016203216700_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-20-1395","article-title":"Designing evolutionary-based interception strategies to block the transition from precursor phases to multiple myeloma","volume":"27","author":"Maura","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025013016203216700_bib18","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"2025013016203216700_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.mayocp.2012.06.014","article-title":"Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition","volume":"87","author":"Therneau","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2025013016203216700_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-021-00406-6","article-title":"Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)","volume":"11","author":"Pang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"14","key":"2025013016203216700_bib21","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2022017094","article-title":"High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025013016203216700_bib22","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/bioinformatics\/btaa895","article-title":"Sigflow: an automated and comprehensive pipeline for cancer genome mutational signature analysis","volume":"37","author":"Wang","year":"2021","journal-title":"Bioinformatics"},{"issue":"10","key":"2025013016203216700_bib23","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/2159-8290.CD-23-1249","article-title":"The history of chromosomal instability in genome doubled tumors","volume":"14","author":"Baker","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"2025013016203216700_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cell.2018.02.020","article-title":"Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal","volume":"173","author":"Mitchell","year":"2018","journal-title":"Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/5\/520\/2353537\/blood_bld-2024-025250-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/5\/520\/2353537\/blood_bld-2024-025250-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:20:45Z","timestamp":1738254045000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/5\/520\/526097\/Development-of-hyperdiploidy-starts-at-an-early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,1,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025250","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}